LONDON, March 14 /PRNewswire-FirstCall/ -- Curidium Medica plc, today announced that it will be presenting at the Cambridge Healthcare Institute’s Biomarker Series second annual Clinical Biomarker Summit, 19 - 21 March at the Hotel Del Coronado, Coronado, California. Dr. Smita Price, PhD, Director, Psychiatry Research will be presenting at 9:35am on Wednesday, 21 March. Dr. Price will be discussing the application of Curidium’s proprietary Homomatrix tool to psychiatric disorders and will be presenting Curidium’s latest Homomatrix findings indicating statistically significantly different Schizophrenic/Bipolar Disorder patient subgroups.
About Homomatrix
Homomatrix is a fully automated analysis tool that uses proprietary pattern recognition tools and sequences of mathematical algorithms together with state-of-the-art statistical methods to objectively analyse large sets of gene expression and biological data from heterogeneous populations. These analyses can potentially lead to the development of diagnostics that identify treatment-responsive patients and/or patient subgroups, signalling pathways as well as drug targets. It is anticipated that Homomatrix could be of significant value in the drug development arena where the “most likely to respond” patients could be pre-selected to clinical trials.
About Curidium
Curidium is a company focused on identifying targeted medicines to treat patients more effectively. Through the application of its proprietary technology, Homomatrix, Curidium analyses biological data (mRNA/protein data) from patients suffering from complex or multi-factorial diseases. Patient populations with complex disorders are known to be heterogeneous and only certain subgroups of patients respond to a specific treatment. Curidium believes that Homomatrix will ultimately allow for the development of the right drug for the right patient. The Company files patents around the genes and drug targets that are associated with the specific subgroups of patients. Further information on Curidium can be found at the Company’s website: www.curidium.com.
Curidium Medica plc
CONTACT: For further information please contact: Anne Bruinvels,+44-(0)-20-7554-8790, CEO Curidium Medica plc. Rob Smith,+44-(0)-20-7554-8793, Finance Director Curidium Medica plc. Rhodri Cruwys,+44-(0)-20-7448-4400, Corporate Synergy plc
